共 180 条
[1]
Allard B(2017)The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets Immunol Rev 276 121-144
[2]
Longhi MS(2020)The adenosine pathway in immuno-oncology Nat Rev Clin Oncol 17 611-629
[3]
Robson SC(2020)On the mechanism of anti-CD39 immune checkpoint therapy J Immunother Cancer 18 1483-1492
[4]
Stagg J(2017)First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Lancet Oncol 394 1915-1928
[5]
Allard B(2019)Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet 11 983-997
[6]
Allard D(2019)CD73: an emerging checkpoint for cancer immunotherapy Immunotherapy 41 1083-1088
[7]
Buisseret L(2018)Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study Am J Clin Oncol 393 156-167
[8]
Stagg J(2019)Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Lancet 62 2313-2319
[9]
Allard D(1988)Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck Cancer 21 899-684
[10]
Allard B(2021)Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial BMC Cancer 15 681-247